Merit Medical Systems, Inc.

As of October 31, 2025, Merit Medical Systems, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 year-to-date and over the past year, but outperforming it over the 3- and 5-year periods.

As of October 31, 2025, Merit Medical Systems, Inc. shows a mildly bearish trend with daily moving averages indicating bearish signals, while it has outperformed the S&P 500 recently but underperformed year-to-date and over the past year.

As of October 31, 2025, Merit Medical Systems, Inc. shows a mildly bearish trend with mixed technical signals, having outperformed the S&P 500 recently but underperformed significantly year-to-date and over the past year, indicating caution despite short-term strength.

As of October 17, 2025, Merit Medical Systems, Inc. is considered overvalued with a valuation grade of expensive, reflected by its high P/E ratio of 42 and underperformance of -15.36% year-to-date compared to the S&P 500's 13.30% return.

As of October 17, 2025, Merit Medical Systems, Inc. is considered overvalued with a P/E ratio of 42, significantly higher than its peers, and has underperformed the S&P 500 over the past five years, indicating a shift in valuation from fair to expensive.

As of September 8, 2025, Merit Medical Systems, Inc. shows a mildly bearish trend with underperformance against the S&P 500, having a year-to-date return of -13.05% compared to the S&P's 12.22%.

As of September 3, 2025, Merit Medical Systems, Inc. is considered expensive and potentially overvalued with a P/E ratio of 42, an EV to EBITDA ratio of 20.38, and a PEG ratio of 2.12, especially when compared to peers and its underperformance against the S&P 500.

As of April 24, 2025, Merit Medical Systems, Inc. is considered overvalued with a P/E ratio of 42 and an EV to EBITDA of 20.38, compared to more attractive valuations of peers like Lantheus Holdings and Haemonetics, despite a positive return of 12.30% over the past year.

As of May 5, 2025, the market trend is mildly bearish based on bearish MACD and moving averages, despite some mixed signals from Bollinger Bands and KST, indicating uncertainty in the overall outlook.

As of March 2022, the management team of Merit Medical Systems, Inc. includes Mr. Fred Lampropoulos as Chairman, President, and CEO, with Ms. Lynne Ward and several Independent Directors on the Board, including Mr. A. Scott Anderson, Ms. Jill Anderson, Mr. Thomas Gunderson, and Dr. F. Ann Millner.

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures, with a market cap of approximately $5.49 billion and quarterly net sales of $354 million. Key financial metrics include a P/E ratio of 42.00 and a return on equity of 9.28%.

As of Jun 18, Merit Medical Systems, Inc. has a market capitalization of $5.49 billion, with net sales of $1.39 billion and a net profit of $122.27 million over the last four quarters.